Newsroom

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced that the Company has signed a $45 million financing agreement (the “Agreement”) with a U.S. institutional investor (the “Investor”), with the full amount received on the same day. The proceeds will significantly support the execution of the Company’s EAI (Embodied AI) ecosystem strategy. Un...

米国カリフォルニア州アーバイン発--(BUSINESS WIRE)--（ビジネスワイヤ） -- 多様な医療分野にわたるフランチャイズ事業を展開するマネジメント・サービス・オーガニゼーションであるSBC Medical Group Holdings Incorporated（Nasdaq：SBC、以下「当社」といいます。）は、本日、相川佳之医師（以下「売出株主」といいます。）による当社普通株式3,100,000株の引受契約に基づく売出し（以下「本売出し」といいます。）について、公開価格を1株当たり3.25米ドルに決定したことを発表いたしました。加えて、売出株主は、引受会社に対し、45日間のオプションとして当社普通株式を最大465,000株まで追加購入する権利を付与しております。本売出しは、通常の取引完了条件に従い、2026年4月21日頃を目処にクロージングする予定です。 なお、本売出しにおいて、当社自身は普通株式の売出しを行っておらず、本売出しによる手取金はすべて売出株主が受領いたします。 本売出しにおいては、Maxim Group LLCが単独の主幹事（sole book-runni...

IRVINE, Calif.--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the unde...

BEIJING--(BUSINESS WIRE)--Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated inst...

SYDNEY--(BUSINESS WIRE)--New research by Amplitude reveals generational AI trust gap among Australian businesses....

SINGAPORE--(BUSINESS WIRE)--Australia’s non-life insurance industry has been resilient against an increasingly complex and interconnected risk landscape, with total insurance revenue for the non-life market reaching approximately AUD 77.7 billion (USD 54.1 billion) for the fiscal year ended 30 June 2025. According to the Best’s Market Segment Report, “Australia’s Non-Life Insurance Segment: Navigating Growth in a Volatile Landscape,” the 10 leading Australia-based non-life insurers reported a c...

雪梨--(BUSINESS WIRE)--(美國商業資訊)-- 全球首屈一指的一站式視覺溝通平台Canva今日宣布，與Anthropic為期兩年的策略性合作進入新階段，將Canva直接接取Anthropic Labs全新推出的Claude Design。此前一天，Canva剛剛在洛杉磯Canva Create大會上面對6500名現場觀眾發表了Canva AI 2.0。 Canva今日還推出了HTML導入功能，這一全新能力讓使用者可輕鬆將Claude等工具生成的互動式內容導入Canva編輯器，透過拖拽操作實現協同編輯、完善和發表。 此次合作讓Claude Design使用者能夠更輕鬆地將AI生成的草稿和創意轉化為Canva中完全可編輯的設計，使其具備協同性、符合品牌規範，並隨時可以擴充和發表。這一合作填補了目前AI領域的一大空白：將AI生成內容轉化為真實可用的成果。 「創意的起點從未如此簡單，但將其實現的過程仍過於複雜和割裂。十多年來我們一直在解決這一問題，如今每月有超過2.5億人使用Canva，將自己的創意變成真實可用的成果。我們欣然透過與Claude Design的合作進一步擴大自身...

澳大利亚悉尼--(BUSINESS WIRE)--(美国商业资讯)-- 全球领先的一体化视觉传播平台Canva今日宣布，其与Anthropic为期两年的战略合作迈入新阶段。根据该合作，Canva将直接接入Claude Design这一由Anthropic推出的全新设计能力。此项进展紧随Canva在洛杉矶举行的Canva Create大会上，面向6,500名与会者发布Canva AI 2.0之后对外宣布。 Canva同日推出HTML导入功能，这一全新能力使用户能够将通过Claude等工具生成的交互式内容，轻松导入Canva编辑器，在其中进行拖放式协作、优化与发布。 此次合作进一步简化了Claude Design用户的创作流程，使其能够将AI生成的初稿与创意高效转化为在Canva中可全面编辑的设计成果，实现团队协同、统一品牌呈现，并支持规模化应用与发布。同时，这一举措有助于弥合当前AI应用中的一大关键短板——即将AI生成内容转化为真正可用、可执行的实际工作成果。 “创意的产生从未如此便捷，但将其转化为现实成果，仍然面临流程复杂、环节割裂的挑战。十余年来，我们始终致力于解决这一难题。如今，每...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Synthetic Design Lab unveils first advanced logic-gated ADC at AACR 2026, achieving ≥10X improvement in targeted cancer cell killing...

SAN MATEO, Calif.--(BUSINESS WIRE)--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced that the first patient has been dosed with EPI-326 in its global Phase 1 clinical study. EPI-326 is the company’s tissue-selective bispecific antibody that degrades all oncogenic mutant and wild type forms of EGFR for EGFR-driven cancers. The first-in-human study is evaluating EPI-326 in patients with advanced non-small cell lung cancer (NSCLC) and head and neck squa...